Drugs / IFB-088
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03610334 | Jun 2018 → Jun 2019 | — | InFlectis BioScience | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05508074 | Dec 2022 → Nov 2024 | amyotrophic lateral sclerosis | InFlectis BioScience | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-03-01 | Hopstem Biotechnology Inc. | Results 2025【二月精选】领域最新进展 hopstem.com ↗
结果显示，其安全性与耐受性良好，未出现临床意义的不良反应，与此前 1 期研究结果一致。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-01 | Hopstem Biotechnology Inc. | 2025【二月精选】领域最新进展 hopstem.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFB-088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03610334 ↗ |
| Route | Oral | “IFB-088 (2.5-60.0mg) oral capsule” NCT03610334 ↗ |